[go: up one dir, main page]

MX2017000628A - Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. - Google Patents

Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.

Info

Publication number
MX2017000628A
MX2017000628A MX2017000628A MX2017000628A MX2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A
Authority
MX
Mexico
Prior art keywords
methods
hypercholesterolemia
cardiovascular risk
high cardiovascular
present
Prior art date
Application number
MX2017000628A
Other languages
English (en)
Other versions
MX378872B (es
Inventor
Bessac Laurence
Chaudhari Umesh
Hanotin Corinne
A Schwemmer Gipe Daniel
Pordy Robert
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2017000628A publication Critical patent/MX2017000628A/es
Publication of MX378872B publication Critical patent/MX378872B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar la hipercolesterolemia. Los métodos de la presente invención comprenden administrar a un paciente de alto riesgo cardiovascular una composición farmacéutica que comprende un inhibidor de PCSK9. En determinadas modalidades, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9, tal como el anticuerpo ilustrativo referido en la presente descripción como mAb316P. Los métodos de la presente invención son útiles para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia y cardiopatía coronaria (CC) establecida o equivalentes de riesgo de CC no adecuadamente controladas con terapia de estatinas a la dosis máxima tolerada. dosis máxima tolerada.
MX2017000628A 2014-07-16 2015-07-16 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. MX378872B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462025371P 2014-07-16 2014-07-16
US201462043167P 2014-08-28 2014-08-28
US201462080725P 2014-11-17 2014-11-17
US201562132709P 2015-03-13 2015-03-13
EP15305830 2015-05-29
PCT/US2015/040765 WO2016011260A1 (en) 2014-07-16 2015-07-16 Methods for treating high cardiovascular risk patients with hypercholesterolemia

Publications (2)

Publication Number Publication Date
MX2017000628A true MX2017000628A (es) 2017-04-27
MX378872B MX378872B (es) 2025-03-11

Family

ID=53365943

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000628A MX378872B (es) 2014-07-16 2015-07-16 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2021000289A MX2021000289A (es) 2014-07-16 2017-01-13 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000289A MX2021000289A (es) 2014-07-16 2017-01-13 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.

Country Status (12)

Country Link
US (2) US20160137746A1 (es)
EP (2) EP3753575A1 (es)
JP (1) JP6912374B2 (es)
KR (3) KR102482375B1 (es)
CN (2) CN107106678A (es)
AU (1) AU2015289617B2 (es)
CA (1) CA2955304C (es)
MX (2) MX378872B (es)
PL (1) PL3169362T3 (es)
RU (1) RU2723018C2 (es)
WO (1) WO2016011260A1 (es)
ZA (1) ZA201700196B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR20200133826A (ko) 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2014197752A1 (en) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
AU2015289613B2 (en) 2014-07-16 2021-07-01 Regeneron Pharmaceuticals, Inc. Methods for treating patients with heterozygous familial hypercholesterolemia (heFH)
WO2016046684A1 (en) * 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
MX2018002000A (es) 2015-08-18 2018-06-19 Regeneron Pharma Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
AU2017227713B2 (en) 2016-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
TW202310872A (zh) * 2017-06-09 2023-03-16 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
IL277127B2 (en) * 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
US20230312750A1 (en) * 2019-11-18 2023-10-05 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
US20220072127A1 (en) * 2020-08-07 2022-03-10 Regeneron Pharmaceuticals, Inc. Methods for treating patients with refractory hypercholesterolemia
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR20200133826A (ko) * 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
HUE069234T2 (hu) * 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk

Also Published As

Publication number Publication date
CA2955304C (en) 2023-12-12
KR20230007538A (ko) 2023-01-12
KR102482375B1 (ko) 2022-12-29
US20200255544A1 (en) 2020-08-13
KR20170028441A (ko) 2017-03-13
RU2017104799A (ru) 2018-08-16
CN114306592A (zh) 2022-04-12
MX378872B (es) 2025-03-11
CN107106678A (zh) 2017-08-29
MX2021000289A (es) 2021-03-31
EP3169362A1 (en) 2017-05-24
ZA201700196B (en) 2024-09-25
CA2955304A1 (en) 2016-01-21
JP2017522316A (ja) 2017-08-10
KR20240132123A (ko) 2024-09-02
PL3169362T3 (pl) 2020-12-28
RU2017104799A3 (es) 2019-02-19
AU2015289617B2 (en) 2021-04-15
EP3753575A1 (en) 2020-12-23
EP3169362B1 (en) 2020-06-10
WO2016011260A1 (en) 2016-01-21
JP6912374B2 (ja) 2021-08-04
US20160137746A1 (en) 2016-05-19
AU2015289617A1 (en) 2017-02-02
RU2723018C2 (ru) 2020-06-08

Similar Documents

Publication Publication Date Title
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2019003134A (es) Terapia de combinacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina